Senescence-directed nanoparticles target fibrotic and immune-excluding tumor environments
Published in Biology, Immunology, Journals, Nanomedicine.
Published October 26, 2026.
A Nature Reviews Drug Discovery highlight published today draws attention to a September 24 Science study by Clemens Hinterleitner and colleagues on nanoparticles directed at disease-associated senescent-like cells.
The researchers identified P-selectin on a subset of these cells in fibrotic tissues and tumors. They used fucoidan-based nanoparticles that bind P-selectin to deliver senescence-modulating treatments, aiming to address harmful cell states more selectively.
In preclinical fibrosis and cancer models, the approach produced antifibrotic and immune-modulating effects. The work identified an immunosuppressive macrophage population as an important functional target. Remodeling fibrotic tumor environments improved immune infiltration and sensitivity to immune checkpoint therapies.
The distinction matters: this strategy targets selected pathological cell populations rather than assuming that every senescent cell should be removed. The findings do not establish a general anti-aging treatment or clinical effectiveness in patients. Human tissue observations support biological relevance, but therapeutic results in experimental models still require clinical validation.
Sources: Hinterleitner et al., Science, September 24, 2026; Crunkhorn, Nature Reviews Drug Discovery, October 26, 2026.